Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹385 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Insecticides India reported a resilient 8% revenue growth in Q3 FY26 despite a challenging operating environment marked by weak farmer sentiment, erratic rainfall, and low pest incidence. Growth was volume-led, driven primarily by the B2B segment, while B2C demand remained muted. Gross margins moderated due to higher B2B mix and limited pricing power, with management cautioning that maintaining 35% gross margins in H2 will be difficult. The company expects Q4 to remain subdued with continued margin pressure, but targets a return to 8-10% sustainable growth over the next 2-3 years, supported by new product launches (Sparkle, Centron, Million) and capacity expansion at Dahej. Key risks include elevated sales returns (₹50 crore in Q3, up 30-40% YoY), pricing pressure from Chinese imports, and the phase-out of Monocrotophos (₹70 crore gross sales). Management emphasized disciplined capital allocation and a focus on premium products (Maharatnas) to drive long-term profitability.
Colored figures show movement against the previous available record.
Guidance to track
- Management targets a return to 8-10% revenue growth over the next 2-3 years, driven by new products and market recovery.
- At least five new products will be launched in Q1 FY27, including three exclusive products and two generics.
- The new formulation facility at Dahej is expected to start operations in Q1 FY27, with the technical plant following in FY27.
- Management expects to end FY26 with double-digit EBITDA margins, despite pressure in H2.
Risks flagged
- Sales returns reached ₹50 crore in Q3, up 30-40% YoY, driven by excess channel inventory and weak demand. This could pressure working capital and profitability.
- The ban on Monocrotophos (final year) will result in a loss of ~₹70 crore gross sales, which may not be fully offset by new products.
- Chinese agrochemical prices remain near two-decade lows, and any further depreciation of the rupee could intensify pricing pressure on domestic players.
- Higher reliance on B2B sales (lower margin) to achieve topline targets is compressing gross margins, with management unable to quantify the impact.
Key quotes
- Q4 is about control, defense, preparation and not short-term optimism. Priority remains in preserving long-term competitiveness.
- This is not a structural margin erosion. The current phase is driven by market conditions, product mix, tactical business decisions.
- The prices are already near the bottom so further deterioration is not expected because many of the prices are all-time low, I can vouch almost two decades.
Research modules